Traws Pharma Inc
Research Traws Pharma Inc (TRAW) on Bullrun: market cap USD 8.79M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTRAW
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 8.79M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 7.11M
- Free cash flow-USD 2.58M
Valuation Snapshot
latest market cap is USD 8.79M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.79M | USD 9.17M | -USD 20.77M | n/a | 0.82 | USD 3.82M | n/a | -USD 629.00K |
| FY2024 | USD 226.00K | -USD 166.52M | -USD 33.44M | n/a | -35.21 | USD 21.34M | n/a | -USD 31.63M |
| FY2023 | USD 226.00K | -USD 18.95M | -USD 17.95M | n/a | -22.57 | USD 20.56M | n/a | USD 10.67M |
| FY2022 | USD 226.00K | -USD 18.96M | n/a | n/a | -0.91 | USD 38.52M | n/a | USD 28.31M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 8.79M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 10.25M | 0.8 | n/a | n/a |
| 2024 | 2024-12-31 | USD 32.42M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 15.75M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 13.60M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 53.28M | n/a | n/a | n/a |
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Traws Pharma Inc's market cap?
Traws Pharma Inc's market capitalization is USD 8.79M.
What does Traws Pharma Inc do?
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.